Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho Invites Applications for Designation as “Global Clinical Research Centers”
November 9, 2009
- Eisai Opens Regional Office in Bahrain
November 9, 2009
- JAPhMed Calls For Increases in Transparency in Research Donations
November 9, 2009
- Eiken Chemical Launches Reagents for New-Type Influenza Virus
November 9, 2009
- AZ to Apply for Vandetanib within 2009
November 9, 2009
- Terumo to Increase Focus on Relief of Cancer Pain
November 9, 2009
- Eisai Ties Up with Quintiles to Develop Anticancer Drug Candidates
November 9, 2009
- Pharm. Business Will Continue to Growth: Mr Ludwig of BD
November 9, 2009
- REGULATORY NEWS IN BRIEF
November 9, 2009
- Half-Year Business Results of Major Domestic Companies
November 9, 2009
- 3 Societies Call For Vaccination of Girls Aged 11-14 with Cervarix
November 9, 2009
- Astellas Licenses MDV3100 for Prostate Cancer from Medivation
November 9, 2009
- PMDA Needs 2,000-3,000 Staff Members for Simultaneous Approval with US, EU: Chief Executive Kondo
November 9, 2009
- Japan Is the Most Important Market in Asia: Mr Barr of Covance
November 9, 2009
- Korosho Considers Extension of Tax Break on Research Expenses
November 9, 2009
- Takeda to Develop Global Business as “Medium-Sized Global Pharma”: Mr Hasegawa
November 9, 2009
- Japan Is Obliged to Promote Use of Generics: Dr Suzuki
November 9, 2009
- Medipal Aims at Sales of ¥30 Bil. in China in FY2012
November 9, 2009
- BioWa Licenses POTELLIGENT Technology to NKTT
November 2, 2009
- 3 JMA Top Management Team Members Not Reappointed as Chuikyo Members
November 2, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…